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Abstract  
Urinary catheters have been used on an intermittent or indwelling basis for centuries, in order 
to relieve urinary retention and incontinence. Nevertheless, the use of urinary catheters in the 
clinical setting is fraught with complication, the most common of which is the development 
of nosocomial urinary tract infections (UTIs), known as catheter-associated urinary tract 
infections (CAUTIs). Infections of this nature are not only significant owing to their high 
incidence rate and subsequent economic burden, but also to the severe medical consecutions 
that result. A range of techniques have been employed in recent years, utilising various 
technologies in attempts to counteract the perilous medical cascade following catheter 
blockage. This review will focus on the current advancement (within the last 10 years) in 
prevention of encrustation and blockage of long-term indwelling catheters both from 
engineering and medical perspectives, with particular emphasis on the importance of stimuli-
responsive systems. 
Keywords  
Catheter-associated urinary tract infection, Proteus mirabilis, biofilm, hydrogel, 
bacteriophage  
Introduction  
The Clinical Problem: CAUTI 
Of the approximately 100 million catheters sold annually worldwide,
1
 the most commonly 
employed in the healthcare setting is the Foley indwelling urinary catheter, which constitutes 
a flexible silicone or latex tube (inserted into the bladder via the urethra), held in place by an 
inflatable balloon and connected to a drainage bag, thus completing the sterile closed-
drainage system. In the UK alone, complications arising from the use of Foley catheters cost 
the National Health Service (NHS) between £1.0-2.5 billion, and accounts for approximately 
2100 deaths annually.
2
 CAUTIs constitute 80% of all nosocomial UTIs, thus comprising over 
40% of all nosocomial infections in the USA alone.
3,4
 
Page 1 of 27
http://mc.manuscriptcentral.com/(site)
Journal name
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Despite innate mechanical safeguards against microbial invasion of the urinary tract, specific 
pathogens are capable of colonising and thriving in this environmental niche. Within the 
healthy, uncatheterised urinary tract, the regular flushing of the urethra as a result of bladder 
emptying helps to impede ascending infection of the urinary tract by mechanical means.
5
 
Further biological safeguards such as the lining of the bladder with urothelial cells (covered 
with a glycosaminoglycan mucin), also helps to mitigate infection by resisting adherence via 
the activation of microbial-sensing proteins, thus triggering the host defences with a cascade 
of cellular and molecular effectors.
6
 Catheterisation of the urinary tract provides opportunities 
that may be exploited by uropathogenic species for avoidance of such safeguards, thus 
resulting in successful colonisation and an increase in patient susceptibility to UTIs.
7
 The 
majority of opportunistic uropathogens are faecal contaminants or skin residents from the 
patient’s own native or transitory microflora, originating in the periurethral area.
8,9
 Bacterial 
entry into the bladder may occur at the point of catheterisation, through the catheter lumen, or 
along the catheter-urethral interface.
10
 Approximately two thirds of bladder colonisation 
during CAUTI occurs via the extraluminal route, where organisms ascend from the urethral 
meatus, via the catheter/urethra interface. Less common is bladder colonisation via the 
intraluminal route (approximately one third of CAUTI), where bacterial cells transfer into the 
bladder as a result of manipulation of the sterile closed drainage system.
11,12
 
Catheter-associated bacteriuria (CAB) is defined as the presence of ≥10
5
 colony forming 
units per millilitre (CFU/ml) of one or more bacterial species in a single catheter urine 
sample. It is generally universal in patients undergoing long-term indwelling catheterization, 
and is detected in the majority of patients who have been catheterised for > 1week.
13
 
Fortunately, most cases of CAB are asymptomatic and are thus commonly referred to as 
catheter-associated asymptomatic bacteriuria (CAASB). Antibiotic prophylaxis is not 
recommended for CAASB, although it may postpone biofilm infections for 1-2 weeks.
14
 
Indeed, the ECDPC recently reported that the most common isolates from CAUTI are 
resistant to at least one of the antimicrobial agents commonly used in clinical practice. 
Namely, 26.3% of E. coli isolates are resistant to third-generation cephalosporins, 26.6% of 
P. aeruginosa isolates are resistant to ceftazidime ,and 9.5% of Enterococcus sp. Isolated are 
resistant to vancomycin.
15
 
 In contrast, the term CAUTI is used to refer to individuals suffering from symptomatic 
infection that is significant bacteriuria as well of symptoms of infection in the absence of any 
other identifiable sources. Although fewer than 3% of patients with CAASB develop 
bacteraemia, given the prevalence of infections of this nature, CAUTI is one of the most 
common causes of secondary bloodstream infection in acute care facilities. Additionally, 
CAUTI is the source of over 50% of episodes of blood stream infections within the long-term 
care setting.
16
 
History and Development of the Foley Catheter 
Derived from the ancient Greek kathiénai, the word catheter can be literally translated as “to 
thrust into”, or “to send down”, and is used to describe an instrument used to drain fluid from 
a body cavity. Since its initial inception into human medicine more than 3500 years ago, a 
vast array of materials and designs have been employed to drain the dysfunctional bladder. 
Early documentation reveals that metals (such as copper, tin, bronze and gold) were used by 
the Greek physiologist Erasistratus in the third century B.C.
17
 Egyptians utilised lead and 
papyrus in the design and manufacture of early catheter models,
18
 whilst the Chinese in 100 
B.C. exploited organic materials such as palm leaves, dried reeds or hollow onion stems that 
were lacquered as urological devices.
19
 The first example of a flexible catheter made of 
malleable gum-elastic was created by Bernard (a French jeweller and goldsmith) in the late 
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18
th
 century, following the development of natural rubber in 1735.
17
 Difficulties in achieving 
a compromise between rigidity and flexibility were not overcome until the vulcanisation of 
rubber was discovered by Charles Goodyear in 1839. 
19
The concept of a catheter retention 
balloon was introduced in 1853, using rubber or woven fabric dipped in linseed oil and 
baked.
20
 The modern-day Foley catheter, used within the acute care and community settings 
today, was first introduced in the mid-1930s by Dr. Frederick B. Foley.
21
 Despite being one 
of the most commonly used medical devices employed within modern medicine, and the 
cornerstone for the management of urinary incontinence, the Foley catheter has opened a 
Pandora’s Box of medical complications, owing to its inherent design flaws and vulnerability 
to rapid-onset bacteriuria.
5
 
Long Term Indwelling Catheters 
Duration of catheterisation is the most important risk-factor associated with CAUTI. 
Approximately 10-50% of patients undergoing short-term or intermittent catheterisation (1-7 
days) develop bacteriuria, whereas catheterisation for >28 days often results in the 
development of CAUTI.
22
 Encrustation and blockage following infection by Proteus 
mirabilis (P. mirabilis) is a common complication associated with urinary devices, and is a 
major cause of morbidity and mortality in CAUTI.
23
 
Proteus mirabilis: Pathogenesis and Mechanisms of Catheter 
Encrustation  
P. mirabilis are Gram-negative members of the family Enterobacteriaceae, distinguishable 
from almost any other genera by their striking ability to swarm across a solid surface.
24
 
Indwelling urinary catheters serve as the ideal initiation site of infection by P. mirabilis. This 
pathogen has been shown to have the greatest ability to attach to catheter surfaces (including 
ethylene, propylene, polystyrene, sulfonated polystyrene, silicone and red rubber catheters) 
than any other Gram-negative organism.
24,25
 There is strong epidemiological and 
experimental evidence that P. mirabilis is the major cause of catheter encrustation,
26
 and has 
been found to colonise approximately 40% of all chronic indwelling catheters.
16
 
Within the catheterised urinary tract, microorganisms not only live as planktonic cultures of 
dispersed single cells, but tend to accumulate at interfaces to form polymicrobial aggregates 
known as biofilms. Biofilms comprise communities of surface-attached cells, embedded into 
an extracellular polymeric matrix. Biofilm formation occurs as a result of complex intra- and 
intercellular signalling and coordinated communication processes, mainly regulated by the 
quorum sensing system ubiquitous in the bacterial world.
3,27
 Biofilms initially formed on the 
catheter surface tend to be monomicrobial, although often develop into polymicrobial 
structures during long-term catheterisation, with up to 72% of catheters being colonised by 
two or more species,
28
 including combinations of P. mirabilis, Morganella morganii, 
Providencia stuartii, Escherichia coli (E. coli), Pseudamonas aeruginosa (P. aeruginosa) and 
Klebsiella pneumoniae.
29–31
 
Although P. mirabilis is generally not the first organism found to colonise the catheter 
surface, it is common and of great significance in long-term catheterisation (Figure 1). 
Indeed, the most frequent causative agent for UTI in humans (approximately 80%), and one 
of the most common causes of Gram-negative bacteraemia in hospitalised patients is E. coli. 
3
 
The longer a catheter is in place, the more like it is to become colonized by P. mirabilis. 
Since P. mirabilis biofilms are both more copious and more likely to cause blockage than 
those of other species, the focus of this review will henceforth be on infection, biofilm 
formation, and subsequent blockage of catheters following infection by this specied in 
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particular.
16
  P. mirabilis is able to express a wide variety of virulence factors, perhaps the 
most relevant of which in terms of CAUTI initiation and establishment is the expression of a 
potent urease enzyme; a cytoplasmic nickel metalloenzyme whose upregulation is initiated by 
a shift to host body temperature and high concentrations of urea.
32,33
Urease induces the 
hydrolysis of urea to ammonia and carbon dioxide, thus elevating urinary pH and facilitating 
the precipitation of polyvalent ions within the urine. The resultant formation of struvite 
(magnesium ammonium phosphate) and apatite (calcium phosphate) crystals typically occurs 
when the urine pH is elevated to ̴8.2,
34
 and such crystals may then accumulate within the 
biofilms on the external and luminal catheter surfaces, obstructing urine flow and leading to 
complications such as incontinence and painful distention of the bladder (owing to urinary 
retention). This in turn leads to severe sequelae such as vesicoureteral reflux, bacteriuria, and 
ascending infection resulting in possible pyelonephritis and septicaemia.
30
  
Furthermore, P. mirabilis is capable of producing an arsenal of bacterial toxins, two of which 
(haemolysin (HpmA) and Proteus toxic agglutinin (Pta), are involved in the process of tissue 
damage and renal migration, thus inducing acute pyelonephritis.
35,36
 HpmA is a Ca
2+
-
dependent pore-forming cytolysin, which achieves destabilisation of the host cell by inserting 
into the cell membrane, causing Na
+
 efflux. Pta is a surface-associated cytotoxic protease, 
functional only at the high urinary pH consequential of P. mirabilis urease. It achieves 
bladder and kidney damage via damage to the structural integrity of the native cells. In the 
proposed mechanism of action, Pta punctures the host cell membrane, inducing cytosol 
leakage, osmotic stress and depolymerisation of actin filaments.
4,37
 
 
[Insert Figure 1] 
This review endeavors to present a range of novel approaches to biofilm reduction and 
eradication. The emphasis is mainly on techniques that are not yet clinically tested, but 
nevertheless have shown significant promise in lab-based trials for the application of 
delay/prevention of catheter blockage following infection by Proteus mirabilis. Some 
methods discussed may have not been utilized in the field of catheter encrustation to date, 
although demonstrate many aspects of transferable technology which may prove useful for 
the future of CAUTI management.  
Part I: Engineering Approaches  
 Passive Release Coatings 
Release-based coatings exert their antibacterial activity by leaching antibacterial compounds 
over time, exposing and subsequently killing bacterial cells both adhered and planktonic. In 
contrast to traditional methods of administering antibacterial agents, release coatings provide 
the ability to deliver agents at a high local concentration, whilst limiting systemic exposure 
and toxicity. Passive release of antimicrobial agents aims to achieve effective prophylaxis as 
well as potential treatment of established bacteriuria, although the reservoirs of antimicrobial 
cargos are inherently limited, thus their action is ultimately temporary. Unlike the stimuli-
responsive approaches discussed in Part III, passive release kinetic profiles generally follow 
first- or second- order kinetics, where an initial burst release is followed by a decreasing tail 
distribution.
38
 The timeframe of the concentration decline is highly application-dependent, 
although generally varies from hours to days, providing a significant challenge in coating 
design, specifically compromising between medical device function and sufficient cargo 
concentration within the carrier matrix. To date, the design of coatings that maintain 
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antimicrobial concentrations throughout the therapeutic window, sufficient to kill bacteria but 
low enough to limit eukaryotic cytotoxicity, remains a significant challenge.
39
 
 
Emerging Developments in Catheter Coatings 
Over the past decade, imbibing or coating medical implants in antimicrobial solutions has 
been commonly used to control infection. A broad range of passive release-based systems 
have been explored for the prevention or delay of urinary catheter encrustation and blockage, 
the most common of which is simple impregnation, where the agent is held within a reservoir 
and released via diffusion. The lack of a specific bonding mechanism results in rapid 
liberation from the release matrix, which generally utilises a polymeric carrier, for example 
poly(methacrylic acid) (PMMA), poly(vinyl alcohol) (PVA), poly(acrylic acid) (PAA), or 
poly(lactic-co-glycolic acid) (PLGA).
40
  
Other approaches to achieve antimicrobial coatings on urinary catheters whilst avoiding the 
use of a polymeric reservoir include deposition by sonochemcial methods. Shalom et al
41
 
described the coating of urinary catheters with Zn-doped CuO nanoparticles using a high 
energy ultrasonic method, which displayed promising antibiofilm activity and 
biocompatibility as indicated by low in vitro cytotoxicity and negligible associated cytokine 
secretion. Evaluation of coated catheters in vivo using a rabbit model showed that rabbits 
catheterised with uncoated catheters scored positive for CAUTI after 4 days. In contrast, 
rabbits with coated catheters did not exhibit CAUTI until day 7 or remained uninfected for 
the entire duration of the 7-day experiment.  
Nitric oxide (NO), a potent biofilm inhibitor, has also been exploited for use in indwelling 
medical devices.
42–44
 Colleta et al
45
 has investigated the impregnation of commercially 
available silicone Foley catheters with S-nitroso-N-acetyl-D-penicillamine (SNAP) via 
solvent swelling. SNAP acts a synthetic NO donor, exhibiting long-term NO release and 
stability when incorporated into low-water uptake polymers. Cytotoxicity testing using a 
mouse fibroblast cell-line showed that SNAP-impregnated catheters were fully 
biocompatible, whilst assessment of prototype catheters against 3-day P. mirabilis biofilms 
showed a 3-logarithmic reduction in cell viability when compared with control catheter 
segments. SNAP- doped catheter tubing was able to substantially decrease bacterial viability 
at each stage of biofilm maturation, thus making it, at the time of writing, the first example of 
the use of a synthetic NO donor capable of preventing mature P. mirabilis biofilm formation, 
whilst producing stable NO at nontoxic fluxes.  
 
Hydrogels  
Hydrogel coatings have also been employed as drug delivery systems for the potential release 
of therapeutic agents from the catheter surface. Hydrogels are ubiquitous throughout the 
literature and widely accepted as being suitable carrier matrices for the delivery of 
antimicrobial compounds. Hydrogels are cross-linked, insoluble, hydrophilic polymer 
networks capable of entrapping significant volumes of water as their liquid component. 
Hydrophilic coating of catheters provides a number of advantages over standard silicone 
catheters, including reduced patient discomfort, increased lubricity and reduced encrustation 
as a result of decreased microbial cell adhesion at the tissue-biomaterial interface.
46,13,47
 
Hydrogels have been shown to increase aggregation of planktonic cells and newly-nucleated 
crystals, leading to accelerated catheter blockage, although the addition of active agents is 
able to suppress this negative effect.
48
 
Recently, preparation of hyaluronic acid (HA)-based hydrogels crosslinked with poly(methyl 
vinyl ether-alt-maleic acid) by thermal and microwave processes were evaluated as drug 
delivery systems using methylene blue (MB) as a model drug. Synthesised hydrogels showed 
a high affinity for MB, and were capable of sustained release over a period of 48 hours. 
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Additionally, in vitro microbiological assessment of the HA-based hydrogels demonstrated 
resistance to microbial adherence (greater than one-logarithmic reduction when compared 
with a PVC control) when evaluated with representative nosocomial strains of 
Staphylococcus aureus (S. aureus) and P. mirabilis.
49
  
Anti-Adhesion / Antifouling Approaches 
Approaches designed to prevent adhesion of bacteria generally aim to impede biofilm 
formation in its infancy using non-cytotoxic mechanisms (either by unfavourable surface 
topography or surface chemistry). Bacterial adhesion to biomaterial surfaces such as urinary 
catheters is generally described using a two stage model: initial, rapid, reversible adhesion 
(stage 1), mediated by non-specific physicochemical interactions, followed by secondary 
‘locking’ adhesion (stage 2) involving specific bacterial-adhesion proteins.
50
 Since the host-
derived conditioning film of urinary components begins development upon insertion of the 
Foley catheter, any existing surface properties of the material are often concealed, and 
pathogen attachment promoted. Therefore, development of antifouling coatings must target 
not only uropathogen attachment but urinary constituents as well. Whilst the conceptual 
simplicity and potential biocompatibility of anti-adhesion coatings makes them an appealing 
approach, their antibacterial action requires extremely close proximity with bacterial cells. 
Surfaces such as catheters may become rapidly contaminated with non-specifically attached 
materials or dead cells, thus compromising the defect-free surface. Consequently, large-scale 
production and subsequent handling may prove challenging in future.  
 
Poly(ethylene glycol) (PEG)-Based Approaches 
The field of antifouling polymers is fast-growing, with new polymer structures being 
frequently designed for this specific purpose.
51
 Poly(ethylene glycol) (PEG) has been the 
most widely used polymer for antifouling in recent years,
52,53
 although its efficacy is 
dependent upon the surface grafting technique and polymeric architecture.
54
 Development of 
anti-fouling coatings of marine mussel adhesive protein mimics conjugated to 3,4-
dihydroxyphenyl-L-alanine-modified poly (ethylene glycol) (mPEG-DOPA(3)) was shown to 
resist both urinary film formation and uropathogenic attachment in vitro when tested with a 
number of relevant isolates on TiO2 disks,
55
 although further randomised and large-scale 
clinical studies are necessary to determine the validity of these coatings. 
 
Zwitterionic Approaches 
Zwitterionic materials, containing equal positive and negative charge functionalities, 
maintain electric neutrality and are well-known for their superior antifouling properties.
56,57
 
Zwitterionic coatings have recently been applied to polydimethylsiloxane (PDMS), the 
material most commonly used for the production of silicone Foley catheters.
58–60
 The 
incorporation of silver into zwitterionic coatings provides an additional aspect to antifouling 
coatings of this nature, and has been under recent investigation in several, broad scientific 
disciplines including membrane processes for water treatment and desalination.
61
 The loading 
of zwitterionic polymer brushes with Ag
+
 precursor ions, followed by their in situ reduction 
to Ag nanoparticles by UV irradiation was investigated by Hu et al.
62
The obtained organic-
inorganic hybrid was capable of killing E.coli (>99.8% in 1 hour) upon contact with 
embedded silver nanoparticles, and subsequently releasing dead bacterial cells under wet 
conditions, preventing the associated immune response and blocking of the antimicrobial 
function. Similar technology has also been assessed in the terms of wound healing,
63
 via 
impregnation of synthesised in situ silver nanoparticles into an antifouling zwitterionic 
hydrogel, thus eliminating the need for additional chemical reductants or toxic solvents. Such 
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applications may also be transferrable to the field of urinary catheters, via coating of the outer 
or inner luminal surfaces with such antimicrobial and antifouling hydrogels.  
 
Surface Topographical Approaches and Nanostructured Materials 
The material and resulting surface topography from which a urinary catheter is made can 
significantly impact the rate of biofilm formation. Latex catheters have a far more uneven 
surface topography than their silicone counterparts, which promotes microbial adherence, 
thus accelerating biofilm formation.
64
 Recent studies have aimed to investigate and exploit 
the abilities of a material’s surface topography in order to modulate cellular adhesion. 
Patterned surfaces, such as Sharklet™ have shown great promise of being a benign surface 
treatment for the prevention of bacterial attachment.
65,66
 Reddy et al
67
 assessed the ability of 
uropathogenic E. coli to colonise three variations of the Sharklet micropattern compared to a 
standard silicone control. All three variations outperformed controls in the prevention of E. 
coli colonisation. An average of 47% reduction in colony-forming units and bacterial area 
coverage was observed, in addition to 77% reduction in colony size in both tryptic soy broth 
(TSB) and artificial urine. 
Contact Killing and Non-Release-Based Approaches 
Contact killing approaches have gained attention in recent years owing to their ability to 
circumvent the issue of reservoir exhaustion synonymous with antibacterial agent release 
coatings. Instead, antimicrobial compounds are covalently anchored to the material surface 
via polymeric linkers. Bacterial attachment and proliferation is subsequently hindered by 
such compounds, generally as a result of disruption to the cell membrane via physical lysis or 
charge disruption.
39
  
 
Catheter Surface Functionalisation: Plasma Deposition 
Among methods of antibacterial surface modification of abiotic surfaces, plasma 
modification plays a rare but increasingly relevant role. With requirements for methods of 
covalent attachment alternative to solvent-based methods, plasma presents an attractive 
alternative deposition method which combines ease of preparation and versatility with 
economical and solvent-free processing. Plasmas, often referred to as the fourth state of 
matter, are typically generated via the ionisation of a gas by electrical discharge, forming 
charged particles including ions, electrons and radicals. The species generated exhibit a 
strong collective response to an applied magnetic field, thus interacting with and modifying 
surfaces via etching, implantation, deposition or functionalisation.
39
 
Applications of plasma-treated surfaces per se, to deter bacterial attachment have generally 
not proved promising, as the arsenal of chemical species available via plasma deposition is 
limited and does not compete with the complexity of the bacterial attachment process.
68
 A 
number of studies have used plasma polymerisation to form interlayers for the covalent 
grafting of antifouling PEG hydrogel layers,
69,70
 including the plasma polymerisation of PEG-
like tetra(ethylene glycol) dimethyl ether on to titanium surfaces for reduction of bacterial 
adhesion to dental implants. The antifouling effect of the coatings was studied by the 
fluorescent staining of bovine serum albumin (BSA), and showed a reduction in protein 
adsorption and cell adhesion without any significant cytotoxic effects.
71
 
Other approaches of functionalising surfaces to repel/kill bacteria using plasma include 
deposited composite coatings embedding organic
72–74
/inorganic antibacterial agents
75,76
, 
which have been reviewed in detail elsewhere.
77
 A recent study attempting to address some 
of the problems of current antibiotic impregnation (including short life-span, narrow 
spectrum, and antibiotic resistance) has recently described the development of anti-biofilm 
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surfaces using bioactive, membrane-targeting antibacterial peptides.
78
 Peptide-immobilised 
surfaces were prepared in a two-step process whereby material samples were first activated 
using argon plasma and then exposed to air to generate hydroperoxide reactive centers. 
Polymer grafted samples were immersed in lytic peptide solution, resulting in immobilisation 
via electrostatic interactions between negatively charged polymer chains and positively 
charged lytic peptides. Evaluation of anti-biofilm surfaces with S. aureus showed treated 
catheters to remain biofilm-free for up to 1 week under conditions of continuous cultivation, 
as well as increased stability of peptide films upon exposure to high concentrations of salt 
and biomacromolecules. Additionally, the low rate of antibiotic resistance and broad 
antibiotic spectrum makes lytic peptides excellent candidates in the future of CAUTI 
treatment. 
Alternatives to the Foley Catheter 
Despite numerous attempts to develop novel coatings and biomaterials to counteract the 
complications associated with long-term indwelling catheterisation, the Foley catheter 
remains the fundamental linchpin in the management of the dysfunctional bladder. Variations 
of the original catheter design,
79,80
 as well as additive devices
81
 to be used with the current 
clinical set up have been explored in order to circumvent the fundamental design flaws of the 
Foley catheter. Levering et al
82
 have recently designed and optimised a urinary catheter 
prototype capable of on-demand biofilm removal in situ. Active surface deformation was 
used to detach biofilms from silicone substrates via utilisation of multi-inflation-lumen 
catheters with four intra-wall inflation lumens, allowing debridement of biofilms from the 
largely-inaccessible main drainage lumen. This extrudable catheter shaft design was able to 
supply sufficient strain around the intra-luminal perimeter to cause mixed-species biofilms of 
P. mirabilis and E. coli to debond from the material surface (Figure 2). Other attempts to 
redesign aspects of the urinary catheter away from Foley’s original prototype include the 
trefoil design described by Sun et al.
83
 The trefoil profile of the catheter proved successful in 
delaying the appearance of culturable organisms when tested in a small in vivo trial in rabbits. 
Variation in catheter design such as the trefoil profile may prove promising in the prevention 
of CAUTI. As well as the inherent advantages offered by the design itself, catheters such as 
this may also still be coated with passive or stimuli-responsive release coatings, thus giving 
the catheter a multifaceted approach to prevention of encrustation and blockage.  
 
[Insert Figure 2] 
Infection Detection Systems 
A recently emerging approach to reduce associated patient morbidity and mortality is the 
detection of the crystalline biofilm formation in advance of catheter blockage. Thus, the 
catheter may be removed or replaced before the onset of the cascade of associated sequelae. 
Currently, there is no reliable way of preventing or accurately predicting when blockage may 
occur.
84
 Patients whose catheters are known to block regularly may be scheduled regular 
catheter changes, however the unpredictability of catheter blockage remains, often resulting 
in emergency changes and the associated patient trauma and healthcare costs.
85
  
In the case of long-term indwelling urinary catheters, freshly obtained urine from the 
catheterised bladder processed gives 50% more false negatives than urine evaluated in the 
same way from non-catheterised patients.
14
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A simple sensor described by Stickler et al
86
 provides a colorimetric signal to warn of 
impending blockage. The sensor, located within the closed catheter drainage system, employs 
the dye bromothymol blue (BMB), which displays a pH-dependent colour change over the 
pH range of 6-8 (yellow to dark blue). Initial testing of cellulose acetate/BMB sensors in vitro 
was capable of giving a clear signal of P. mirabilis infection using pH as a proxy indicator. 
Further development of this system to enable larger scale manufacture employed a silicone-
based composite strip design via combination of BMB with polydimethylsiloxanes and a 
hydrophobic filler.
87
 The resultant strips of sensor material may be housed in a connector and 
placed within the junction between catheter and drainage bag, where they achieved the same 
yellow to blue colour change over the desired pH range approximately 19 hours in advance of 
blockage. Clinical evaluation of this system undertaken by Long et al
88
 showed promising 
results, however the mean time between sensor colour change and catheter blockage was 
considerably longer in human trials than in the in vitro model resulting in an advanced 
warning of >19 days for the modified design. 
Another dye-based diagnostic system, utilises a dual-layered polymeric system in the form of 
a catheter coating, whereupon a urinary colour change is resultant from an increase in urinary 
pH.
89
 The system constitutes a lower hydrogel reservoir layer of ploy(vinyl alcohol) 
containing the self-quenching dye 5(6)-carboxyfluorescein, completely capped and sealed by 
an upper layer of the pH-responsive polymer poly(methyl methacrylate-co-methacrylic acid 
(EUDRAGITS 100®). Following infection by P. mirabilis and subsequent formation of 
alkaline urine, the outer layer of the coating swells to release the dye in its fluorescent form 
into the urine, giving a clear visual warning of impending blockage. In vitro analysis of the 
coatings using a clinically relevant artificial bladder demonstrated up to 12 hours advance 
warning of blockage, exclusively in the presence of urease-positive clinical isolates.  
Surender et al have recently described a luminescent lanthanide pH-responsive probe capable 
of detecting the urease-mediated hydrolysis of urea in aqueous solution.
90
 A series of 
photophysical titrations showed the Eu(III) chelate behave as an “on-off” luminescent 
switching probe, where the luminescence is quenched upon the conversion of urea to 
ammonia and carbon dioxide. Impregnation of water-permeable hydrogels with the 
lanthanide probe showed its potential to be used as a sensor in the field of CAUTI diagnosis 
(Figure 3A+B). Figure 3C shows the excitation spectra of the swollen Eu-based hydrogel, 
before and after the addition of urease. The Eu-centered emission was quenched by more than 
85%, and the resultant colour change from bright red (on) to faint pink (off) was visible to the 
naked eye as well as under UV irradiation.  
  
[Insert Figure 3] 
Part II: Medical Approaches  
Antibiotic-Based Approaches 
Antibiotics have been central to the treatment of bacterial infections (including UTIs) since 
their discovery in 1928. Most cases of CAUTI are usually categorised as asymptomatic and 
thus do not require antibiotic prescription.
7
 However, a number of antimicrobials (such as 
silver alloy and antibiotics) have been approved for use as topical antibacterial impregnated 
catheters for the prophylaxis of CAUTI.
7,91,92
 These include nitrofurans, nitrofurazone and 
nitrofurantoin,  which are known to have a broad spectrum of activity against Gram-negative 
and Gram-positive bacteria, and are less prone to causing bacterial resistance.
91
 Nevertheless, 
these commercially available antimicrobial catheters still lack strong evidence to support 
their routine use in CAUTI management. Clinical trials assessing the performance of silver 
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alloy and nitrofurazone coated catheters in thousands of short-term catheterised patients 
showed no clinically relevant reduction in CAUTI incidence as compared to untreated 
catheters.
92
 Furthermore, these catheter-treatments are vulnerable to P. mirabilis infections as 
silver-coated catheters were found to enhance crystalline biofilm formation, while 
nitrofurazone has little activity against P. mirabilis and lacked effective control of catheter 
blockage.
93,94
 Full analysis of the efficacy of silver/antibiotic coated/impregnated catheters is 
beyond the scope of this review, but can be found elsewhere in the literature.
95–97
 
The biocide triclosan has been tested previously for effective prevention of biofilm formation 
by various uropathogens including P. mirabilis, and prevention of catheter blockage.
98,99
 The 
tests were conducted using representative in vitro models of the catheterized urinary tract, 
simulating a complete closed drainage system as used in clinical practice.
100
 Catheter 
balloons were inflated with triclosan solution (3-10 g/L) diffusing into the bladder lumen in 
sufficient concentrations to prevent catheter encrustation in models inoculated with P. 
mirabilis only
99
 and polymicrobial communities frequently containing P. mirabilis.
98
 
However, it was later revealed that extensive use of triclosan could potentiate an adverse 
therapeutic effect on P. mirabilis. Prolonged exposure of P. mirabilis to triclosan on agar 
plates resulted in selection of P. mirabilis mutants with reduced susceptibility to triclosan up 
to 300-fold, leading to catheter encrustation in models treated with triclosan.
101
  Such 
vulnerability of individual antibiotic therapy, can be minimised by combination of antibiotics 
acting on different targets or using different mechanisms.          
Fisher et al.
102
 have reported impregnation of urinary catheters with a combination of 
rifampicin, sparfloxacin and triclosan (an antibiotic regimen chosen for its broad spectrum 
against CAUTI pathogens). Using a serial bacterial challenge within an in vitro model, 
antibiotic-impregnated catheter sections were inoculated with bacterial suspensions on a 
weekly basis, and antimicrobial activity was compared with two commercial silver-processed 
and nitrofural coated catheters. The novel coating demonstrated prevention of Proteus 
mirabilis, Staphylococcus aureus and Escherichia coli colonisation for 7–12 weeks, 
compared with 1–3 days for the commercially available antimicrobial catheters. No resistance 
was detected with any of the test bacterium during the 12 weeks of the flow challenge test. 
However, P. mirabilis isolates from catheters from week 8 showed a slight decrease in 
susceptibility to the antibiotics, suggesting mutational resistance still occurred. Further 
studies have demonstrated the efficacy of combined antibiotic formulations to control 
CAUTIs. For example azithromycin-ciprofloxacin-impregnated catheters were recently 
shown to avert P. aeruginosa bacterial colonization, prevent biofilm formation, and implant-
mediated inflammation in a murine model.
103
 Evidence from these studies show that 
antibiotic therapy is still relevant in CAUTIs. However the rise of antibacterial resistance, 
where potent antibiotics have been losing their efficacy over time requires alternatives to 
antibiotics.
104
  
Alternatives to Antibiotics 
Bacteriophage 
Bacteriophage (phage) are likely to have high impact as alternatives to antibiotics for the 
control of CAUTIs. Phage are the natural viral predators of bacteria, and the most abundant 
biological entity on earth. Existing in nature as non-living particles,
105
 they selectively infect 
bacteria and disrupt normal bacterial metabolism to self-replicate, and kill the bacterial host 
in the case of lytic phage. Lytic phage, that destroy bacterial cells releasing new phage 
particles are the most suitable for phage therapy and can be effective at a low phage dose.
106
 
Phage have been investigated for their antibacterial efficacy in a number of scientific 
disciplines, particularly within therapeutic delivery.
107
  
Page 10 of 27
http://mc.manuscriptcentral.com/(site)
Journal name
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Phage have showed great promise in a variety of formats including the development of 
antibacterial surfaces and biomaterials. In a study by Wang et al
108
, active lytic bacterial 
viruses (bacteriophage) were immobilised onto polyhydroxyalkanoate (PHA) surfaces to 
form an infective antimicrobial surfaces. T4 bacteriophage (phage) immobilised on the 
surface after treatment with oxygen plasma retained their active conformation and orientation 
and hence were able to result in clear capture and infection of E. coli host cells. No evidence 
of phage binding was observed on untreated control films. (Figure 4).Such technology is 
potentially applicable to the treatment of CAUTI, since most polymers undergo similar 
oxidation during oxygen plasma treatment, thus the technique is widely transferrable to other 
polymeric substrates. 
Recent studies have demonstrated the effect of phage against urinary pathogens using in vitro 
models simulating CAUTIs.
109–114
 Pre-treating hydrogel-coated catheter sections with 
bacteriophages revealed an approximate 90% reduction in biofilm formation in E. coli and P. 
mirabilis species,
109
 and 99.9% reduction in P. aeruginosa biofilms;
110
 both studies employed 
a 24-h incubation static in vitro model. Using a two-species biofilm in a continuous-flow in 
vitro model, Lehman and Donlan
111
 demonstrated the ability of bacteriophage cocktails 
coated within a hydrogel to reduce P. aeruginosa and P. mirabilis biofilms on catheters 
99.9% to 99.8% over 48 hours. Reduction of biofilm formation and prevention of blockage of 
urinary catheters by P. mirabilis were also demonstrated,
113,114
 using representative in vitro 
models of the catheterized urinary tract, simulating a complete closed drainage system as 
used in clinical practice.
100
 When models simulating established infection of 10
10
 cells of P. 
mirabilis, were treated by a single dose of phage, directly added into the infected bladder 
model, the therapy significantly increased time taken for catheters to block (∼3-fold). Phage 
therapy was able to completely eradicate early-stage infection consisting of 10
3 
cells of P. 
mirabilis, when challenged with 10
10
 phage in bladder models. In these experiments, no 
viable bacterial cell was recovered from bladder model residual urine, whereas phage 
particles were still found to be present inside bladder models 8 days after model activation.
113
  
 
[Insert Figure 4] 
 
These studies suggest that high doses of phage delivered at an early stage of infection could 
lead to effective phage therapy, which is often hampered by  development of phage-resistance 
reported in models with established infections.
111,113
 Development of bacterial resistance to 
phage infection is usually caused by spontaneous mutations in host cell populations over 
time, or bacterial adaption in response to selective pressure exerted by the bacteriophage.
115
 
This leads to modifications in phage receptors, affecting phage-host interactions and 
efficiency of infection. One way to overcome phage resistance is the use of phage cocktails, 
where multiple phage are used in mixed dose therapy, resulting in broader antibacterial 
spectrum of activity.
116,117
 Despite the great promise that phage therapy has shown 
throughout a number of scientific disciplines in recent years, the regulatory barriers are 
considerable and must be overcome before this can truly be seen as a viable treatment 
option.
107
 
 
Drugs with Efflux Pump Activities  
Efflux pump systems are transport proteins that bacteria use to extrude toxic agents, including 
antibiotics.
118
 In their study investigating the genetic basis of biofilm formation in P. 
mirabilis, Holling et al.
119
 demonstrated that efflux systems are essential in the formation 
of P. mirabilis crystalline biofilms. This was revealed by phenotypic characterisation of P. 
mirabilis mutants, which showed reduced ability to form crystalline biofilms and block 
catheters compared to the wild-type strain. Genetically, these mutants were disrupted in 
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the Bcr/CflA (a subfamily of efflux system).
119
 This discovery led to further investigations for 
the potential for efflux pump inhibitors (EPIs) to control bacterial biofilm formation and 
catheter blockage by P. mirabilis. By screening several drugs already commonly used in 
human medicine, with potential EPI activity in other bacterial species,
120,121
 Nzakizwanayo et 
al.
122
 demonstrated the effect of fluoxetine and thioridazine to act as EPIs in P. mirabilis, and 
control biofilm formation and blockage of catheters. Fluoxetine is a selective serotonin re-
uptake inhibitor (SSRI), marketed as Prozac, and thioridazine is an antipsychotic-drug. This 
study shows that repurposing of existing drugs with EPI activity as a novel approach to 
control catheter blockage.  
 
Quorum-Sensing Inhibitors  
The quorum-sensing (QS) system is a regulatory mechanism by which bacterial cells 
communicate via a chemical vocabulary (e.g. N-acyl homoserine lactones (AHLs) in Gram 
negative bacteria). Concentration of AHLs increases as the bacterial population grows, and 
upon reaching a threshold, binding to receptor molecules occurs. This binding acts as a 
transcriptional regulator on genes of the QS system and contributes to the production of 
virulence factors that aid biofilm formation.
123
Molecules and enzymes targeting this bacterial 
communication system have recently been investigated in the field of CAUTI as novel anti-
biofilm agents. Jones et al
124
 investigated two QS antagonists, tannic acid and p-nitrophenyl 
glycerol, finding that both were capable of controlling the crystalline biofilms of P. mirabilis. 
Anti-biofilm and anti-quorum sensing compounds from secondary metabolites of halophiles 
marine Streptomyces have recently been assessed by Younis et al.
125
Isolate sediment lake 
Iraq (sdLi) showed promising inhibition of P. mirabilis biofilm formation on urinary catheter, 
as well as attenuation of QS-dependent factors such as hemolysin activity, urease activity, pH 
and bacterial motility. 
Coatings utilising the immobilisation of the enzyme acylase (from Aspergillus melleus) on 
biomedical grade polyurethane coatings via multipoint covalent immobilisation have shown 
to have potential in biofilm prevention via quorum sensing-disruption.
126
 Coatings containing 
amylase were shown to enzymatically catalyse the hydrolysis of the quorum sensing 
molecules s N-butyryl-L-homoserine lactone (C4-LHL), N-hexanoyl-Lhomoserine lactone 
(C6-LHL), andN-(3-oxododecanoyl)-L-homoserine lactone (3-oxo-C12-LHL), and showed 
an approximately 60% reduction in biofilm formation by two clinical isolates of P. 
aeruginosa. A similar approach investigated by Ivanova et al.
127
 where multi-layered 
coatings of acylase and α-amylase (able to degrade quorum sensing autoinducers and 
polysaccharides, respectively), deposited on urinary catheters via layer-by-layer techniques 
displayed quorum quenching and matrix-degrading abilities, delaying biofilm growth of 
relevant uropathogens by up to 7 days in vivo. 
Enzymes  
The preparation and antibacterial properties of an enzyme-embedded polycaprolactone 
(PCL)-based coating have been investigated by Dave et al.
128
The coating, impregnated with 
the antibiotic compound gentamicin sulphate (GS), utilises PCL itself as a substrate for the 
enzyme lipase, resulting in release of GS at a rate controlled by degradation of the PCL base. 
Modulation of enzyme concentration in PCL films allowed control of GS release from the 
coating from 16 to 33 days, also resulting in complete degradation of the polymer film so that 
no residual polymer substratum could serve as a base for possible microbial adherence post 
antibiotic release. The polymer showed antibacterial effects against three test isolates: E. coli, 
S. aureus, and P. aeruginosa, and displayed sustained release in vitro over a period of 60 
hours when coated onto urinary catheters. The results suggest that the tunable, self-degrading 
coatings prove a promising candidate for use in urinary catheters, although enzyme 
biocompatibility within the bladder could prove problematic.  
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Enzymes have also been incorporated into catheter lubricants in order to investigate their 
potential in the field of CAUTI. Thallinger et al
129
 examined the ability of cellobiose 
dehydrogenase (CDH) to produce hydrogen peroxide for antibiotic and antibiofilm 
functionalisation of urinary catheters. Biofilm formation of silicone films was prevented by 1 
mM CDH (recombinantly produced from Myriococcum thermophilum), and the growth of 
many common uropathogens, including P. mirabilis, was inhibited. The aforementioned 
antibiofilm activities were found to be strongly enhanced when used in the presence of α-
linked glycosides, as the consequent hydrolysis of polysaccharides increases the number of 
terminal reducing sugars as substrates for CDH as well as causing destabilisation of the 
biofilm.  
 
Part III: Stimuli-Responsive Approaches  
Alongside the current engineering and passive release strategies aimed at preventing catheter 
blockage, additional research has focused on stimuli-responsive systems. Such systems rely 
on an external stimulus (either directly or indirectly associated with the onset of infection) in 
order to facilitate diagnosis or treatment. Direct indicators of infection include specific 
biomarkers produced by pathogenic bacteria (such as enzymes or toxins), whilst a change in 
the local environment may indirectly confirm infection via bacterial or immune activity (e.g. 
a change in pH or temperature). Stimuli-responsive materials retain their diagnostic or 
therapeutic potential until an endogenous factor initiates a burst response of the cargo 
contained within. This may manifest as a change in volume or structure of the material (in the 
case of polymeric or hydrogel formulations), or as a result of bond cleavage of anchored 
moieties.
39
 The ability to control both the release kinetics and the delivery location of a 
diagnostic or therapeutic agent offers certain advantages over conventional passive release 
systems including: protection of the often sensitive cargo from harsh external conditions and 
avoidance of any unnecessary or sub-lethal exposure, thus limiting any subsequent evolution 
of bacterial resistance. The controlled release concept is especially attractive in the treatment 
of CAUTI owing to the time-dependent delivery of the therapeutic cargo. In addition to the 
aforementioned precautions, premature administration of a therapeutic agent to the bladder 
will inevitably result in timely elution, rendering the system ineffective in successfully 
clearing a progressive infection.   
The urease-catalysed conversion of urea into ammonia by certain urinary pathogens (in 
particular P. mirabilis), and the resultant increase in urine pH has been exploited in the 
development of a number of pH-responsive catheter coatings. The pH-responsive polymer 
Eudragit S100® (poly (methylmethacrylate-co-methacrylic acid)) has been developed in 
order to deliver bacteriophage from coated catheters in order to delay blockage. Prior to any 
elevation in urine pH, P. mirabilis bacteriophage contained within the PVA reservoir layer 
are unable to elicit any bactericidal effects. However, upon an infection-associated increase in 
urine pH and the subsequent dissolution of the Eudragit layer, the phage are able to diffuse 
into the bladder, reducing bacterial load by up to 6-log within 2 hours. Overall, this resulted 
in doubling the time to blockage  (26 hours compared to 13 hours for the uncoated catheters), 
ultimately extending the catheter lifetime by 100%.
114
 
An alternative strategy in the development of pH-responsive catheter coatings utilises the 
solubility of specific drug formulations in order to modulate their release from polymeric 
hydrogels. Nalidixic acid (a pH sensitive antimicrobial quinolone) has been successfully 
loaded into polymeric films of poly(2-Hydroxyethylmethacrylate) co-polymerised with 
methyl methacrylate. Owing to the presence of an ionisable carboxyl group within the 
quinolone structure, the mechanism of pH-dependent drug release relies on the affinity of the 
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ionised drug (at alkaline pH) towards aqueous media (urine), resulting in diffusion out of the 
carrier matrix and into the surrounding area. As opposed to conventional polymeric triggered 
release systems, this formulation does not rely on a structural change in the polymeric carrier 
in order to facilitate antimicrobial expulsion, rather the chemical properties of the 
antimicrobial itself govern the rate of drug release. Utilising a hydrophobic polymer, the 
release kinetics of the drug were controlled in order to provide sustained zero-order drug 
diffusion over the course of weeks, as oppose to hours as reported with more hydrophilic 
polymers.
130
 Moreover, a series of polymerisable ester naphthyridinone conjugates have been 
synthesised with varying chain lengths. The base-catalysed hydrolysis of the ester bond 
linking the nalidixic acid to the vinyl spacer arm determines the rate of pH-dependent drug 
release when anchored to polymeric biomaterials.
131
 Further studies have developed this 
concept using the aforementioned vinyl-functionalised nalidixic acid and crosslinked 2-
hydroxyethyl methacrylate hydrogels, forming antimicrobial pro-drug matrices. In-vitro 
results exhibited negligible drug release at physiological pH, while the triggered, prolonged 
release of nalidixic acid was up to 20-fold faster and approximated 80% after 6 weeks at pH 
10.
132
  
In contrast to utilising a change in the external environment, specific bacterial biomarkers 
have been exploited in order to induce the release of antibacterial agents via disassembly of 
polycationic nanospheres. Aminocellulose (AC), an effective antimicrobial agent owing to its 
propensity towards bacterial membrane disruption, has been formulated into nanospheres and 
incorporated into a multi-layer coating capable of preventing P. aeruginosa biofilm 
formation. The formulation compris s AC nanospheres coated with hyaluronic acid, the outer 
layer is degraded by pyocyanin (a redox active virulence factor produced by P. aeruginosa) 
thus liberating the antimicrobial components within. Planktonic bacterial growth was reduced 
by 70% after 2 hours (p < 0.001), whereas under dynamic conditions (bladder model 
experiments) effective catheter biofilm prevention was confirmed via fluorescence 
microscopy as shown in Figure 5.
133
 
 
[Insert Figure 5] 
 
Concluding Remarks and Future Perspective  
Whilst it is widely acknowledged that the clinical, social and economic burden associated 
with the use of the Foley catheter for long-term indwelling catheterisation has gained 
notoriety in recent years, it is also true to say that regulatory authorities, relevant industrial 
and commercial companies as well as the scientific community has thus far failed to seek a 
comprehensive solution. This is likely owing to the fact that in order to achieve such an 
extensive and complex scientific undertaking, the nature of the necessary research is 
inherently multidisciplinary. The marriage of broad and often tenuously linked scientific 
disciplines must occur in order to truly overcome the problem of encrustation and blockage of 
Foley catheters. Indeed, it is the responsibility of the commercial companies and regulatory 
authorities to positively encourage innovation for an application where existing devices are so 
clearly inadequate. Taking into account the research presented in this review, future attempts 
to improve the urinary catheter system must involve the marriage of chemical, biological and 
engineering advancements, whilst still maintaining the assets of the original design. It is 
necessary for research funders, healthcare services and governing bodies to stimulate 
interdisciplinary research amongst the scientific, engineering, industrial and clinical 
communities to meet and overcome the challenge.  
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Moreover, passive release of antimicrobial cargos should not be considered a panacea or 
universally effective strategy as previously regarded. Rather, they should be considered part 
of a concerted effort to control known risk factors of CAUTI, and the basis of more advanced 
and microbiologically fool proof methods, such as stimuli-responsive release. Such ‘smart’ 
coatings provide the basis of a multifaceted solution in which the properties and local 
concentration of the antimicrobial agent are maintained whilst limiting systemic exposure, 
thus taking into consideration the challenge of introducing such species into the catheterised 
bladder. Despite recent advances in this field, several key challenges must be overcome in 
order for triggered release coatings to become a truly valued tool in the CAUTI-preventative 
arsenal, including long term stability, maintenance of catheter functionality and ease of 
commercial manufacture. 
In conclusion, the review has identified the current advances within the fields of medicine 
and biomedical engineering, which must now be used in combination in order to maximise 
their efficacy and broaden their field of application. Despite the large amount of reported 
approaches throughout the literature, few platforms have progressed to clinical studies, and 
even fewer to clinical practice. The lack of translational success can be attributed in part to 
the inherent complexity of the problem and the necessity of the multidisciplinary approach 
necessary to overcome it. Objective evaluations of coating stability, specific to the challenge 
of CAUTI have often been similarly overlooked. Specifically structured research is therefore 
paramount to develop validation methods for technologies such as stimuli responsive 
coatings, such that clinical efficacy may be effectively extrapolated. Overcoming these 
challenges will require collaborative effort from those working across a wide variety of 
disciplines (in particular the field of biomedical science), but success will offer ample 
opportunity for innovation, as well as a long-overdue solution to a complex clinical problem. 
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Figure 1: Flowchart showing the sequential encrustation and blockage of an indwelling urinary catheter 
following infection by Proteus mirabilis.  
 
154x60mm (96 x 96 DPI)  
 
 
Page 23 of 27
http://mc.manuscriptcentral.com/(site)
Journal name
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
  
 
 
Figure 2: Multi-inflation-lumen catheters able to cause debridement of multispecies P. mirabilis and E. coli 
biofilms in situ. Cross sectional images of A) control catheter (no inflation), B) first inflation after 30 hours of 
biofilm growth, C) second inflation after 24 hours biofilm regrowth. D) Sections from which the cross 
sections were obtained: i) bottom, ii) middle, iii) top, and iv) distal tip. Scale bars indicate 1 mm. Reprinted 
from [82]. © 2016, with permission from Elsevier.  
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Figure 3: Assessment of a hydrogel-impregnated supramolecular Eu(III)-based pH-responsive “on-off” 
sensor for CAUTI. A) “on” (before addition of urease), B) “off” (200 minutes after addition of urease) states 
of the hydrogel, when irradiated at λmax = 254 nm. C) Excitation spectra of the swollen Eu-based hydrogel, 
before and 200 minutes after the addition of urease (0.5 U), measured in an aqueous solution of urea (2.3 
x10-3 M) at 295 K. Adapted with permission from [90]. © 2016 American Chemical Society.  
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Figure 4: Fluorescence microscopy images of PHA surfaces treated with oxygen plasma and incubated with 
carrying concentrations (plaque forming units per millilitre (PFU/ml)) of T4 bacteriophage. Top row: 
characterisation of immobilised bacteriophage on PHA. Bottom row: Stained E. coli host cells in stationary 
phase, captured on surfaces with immobilised bacteriophage. A, E) Control films (no bacteriophage). B,F) 
Films prepared with 2 x 108 PFU/ml. C,G) Films prepared with 2 x 109 PFU/ml. D,H) Films prepared with 2 x 
1010 PFU/ml. Both phage and bacterial cells w re stained using SYBR green, 1 hour post-immobilisation and 
prior to exposure, respectively. Reprinted with permission from [108]. © 2016 American Chemical Society.  
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Figure 5: Effect of hyaluronic acid coated AC nanospheres (HA/ACNSS) on P.aeruginosa biofilm 
formation  within the shaft of a foley catheter after 7 hours incubation (bottom), compared to the uncoated 
control catheter (top). Fluorescent microscopy images are 20 x mag with scale bars set at 100 µm. 
Reprinted from [133]. © 2016, with permission from Elsevier.  
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